Brief: Apexigen And Brookline Capital Acquisition Corp Announce Effectiveness Of Registration Statement And Annual Stockholder Meeting To Approve The Proposed Business Combination

Apexigen

18/07/2022 23:47

July 18 (Reuters) - Brookline Capital Acquisition Corp.
 BCAC.O :
    * APEXIGEN AND BROOKLINE CAPITAL ACQUISITION CORP. ANNOUNCE
EFFECTIVENESS OF REGISTRATION STATEMENT AND ANNUAL STOCKHOLDER
MEETING TO APPROVE THE PROPOSED BUSINESS COMBINATION
    * APEXIGEN- THE TRANSACTION VALUES APEXIGEN AT A $205
MILLION
NET-EQUITY BASIS AND INCLUDES A $15 MILLION FULLY COMMITTED PIPE
FINANCING
    * APEXIGEN- EACH WHOLE WARRANT ENTITLED TO PURCHASE ONE
SHARE OF
BCAC COMMON STOCK, AT A PURCHASE PRICE OF $10.00 PER UNIT
    * APEXIGEN- UPON CLOSING OF THE TRANSACTION, BCAC WILL BE
RENAMED
APEXIGEN, INC.
    * APEXIGEN - AFTER CLOSING OF TRANSACTION, NEW CO TO BE LED
BY
XIAODONG YANG, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF APEXIGEN
    * APEXIGEN- UPON CLOSING, CO WILL CONTINUE TO BE LISTED AND
TRADED
ON THE NASDAQ CAPITAL MARKET UNDER THE SYMBOLS “APGN” AND
“APGNW,” RESPECTIVELY

Source text for Eikon:  ID:nGNX8Gg8Hm 
Further company coverage:  BCAC.O 

 ((Reuters.Briefs@thomsonreuters.com;))